ACM
ESPR

Atika Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Atika Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-18,300
Closed -$1.5M – 69
2015
Q2 		$1.5M Buy
+18,300
New +$1.79M 0.67% 51

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Atika Capital Management's ESPR Position: Q2 2018 in Review

Atika Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 40,000 shares — an estimated $2.89M sold.

Atika Capital Management first reported a position in ESPR in Q1 2015 and held it in 5 quarters. The position peaked at $3.69M in Q4 2017. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • Atika Capital Management reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Atika Capital Management sold 40,000 Esperion Therapeutics shares in Q2 2018, an estimated $2.89M.
  • Atika Capital Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 5 quarters.
  • Atika Capital Management's Esperion Therapeutics position peaked at $3.69M in Q4 2017.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on Atika Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.